{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:45:40Z","timestamp":1790343940049,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013920","name":"VHL Alliance","doi-asserted-by":"publisher","award":["PRJ_20450"],"award-info":[{"award-number":["PRJ_20450"]}],"id":[{"id":"10.13039\/100013920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA247439"],"award-info":[{"award-number":["U01 CA247439"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["686061"],"award-info":[{"award-number":["686061"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019418","name":"NIHR Maudsley Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010438","name":"The Francis Crick Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","award":["A29911"],"award-info":[{"award-number":["A29911"]}],"id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","award":["FC10988"],"award-info":[{"award-number":["FC10988"]}],"id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","award":["A109"],"award-info":[{"award-number":["A109"]}],"id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0652"],"award-info":[{"award-number":["W81XWH-22-1-0652"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["A2204"],"award-info":[{"award-number":["A2204"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016916","name":"Royal Marsden Cancer Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["FC010110"],"award-info":[{"award-number":["FC010110"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.esmoop.2025.105109","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T16:49:11Z","timestamp":1747414151000},"page":"105109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel\u2013Lindau (VHL) disease-associated haemangioblastoma"],"prefix":"10.1016","volume":"10","author":[{"given":"S.T.C.","family":"Shepherd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kelly-Morland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Drage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.F.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Macwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Turajlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5112","key":"10.1016\/j.esmoop.2025.105109_bib1","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"issue":"283","key":"10.1016\/j.esmoop.2025.105109_bib2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/qjmed\/77.2.1151","article-title":"Clinical features and natural history of von Hippel-Lindau disease","volume":"77","author":"Maher","year":"1990","journal-title":"Q J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105109_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/jmedgenet-2016-104058","article-title":"Survival and causes of death in patients with von Hippel-Lindau disease","volume":"54","author":"Binderup","year":"2017","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105109_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrc3844","article-title":"VHL, the story of a tumour suppressor gene","volume":"15","author":"Gossage","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105109_bib5","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/jmedgenet-2021-108216","article-title":"Clinical characteristics and risk factors for survival in affected offspring of von Hippel-Lindau disease patients","volume":"59","author":"Zhang","year":"2022","journal-title":"J Med Genet"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105109_bib6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/jmedgenet-2017-104995","article-title":"Risk factors for survival in patients with von Hippel-Lindau disease","volume":"55","author":"Wang","year":"2018","journal-title":"J Med Genet"},{"issue":"18","key":"10.1016\/j.esmoop.2025.105109_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162480","article-title":"Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer","volume":"132","author":"Kaelin","year":"2022","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105109_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(02)00071-5","article-title":"HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron","volume":"1","author":"Mandriota","year":"2002","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105109_bib9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1535-6108(02)00043-0","article-title":"Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein","volume":"1","author":"Kondo","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2025.105109_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/757908","article-title":"Effects of HIF-1alpha and HIF2alpha on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts","volume":"2010","author":"Biswas","year":"2010","journal-title":"J Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105109_bib11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1073\/pnas.0808092106","article-title":"Artificial ligand binding within the HIF2alpha PAS-B domain of the HIF2 transcription factor","volume":"106","author":"Scheuermann","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105109_bib12","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm301847z","article-title":"Development of inhibitors of the PAS-B domain of the HIF-2alpha transcription factor","volume":"56","author":"Rogers","year":"2013","journal-title":"J Med Chem"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105109_bib13","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105109_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105109_bib18","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(24)00389-9","article-title":"Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study","volume":"25","author":"Iliopoulos","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105109_bib19","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2022-0008","article-title":"First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma","volume":"11","author":"Dhawan","year":"2022","journal-title":"CNS Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105109_bib20","article-title":"LITESPARK-022: a phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC)","volume":"40","author":"Choueiri","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105109_bib21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(24)00649-1","article-title":"Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study","volume":"26","author":"Choueiri","year":"2025","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105109_bib22","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105109_bib23","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-2968","article-title":"FDA approval summary: belzutifan for VHL disease tumors\u2014letter","volume":"29","author":"Trinh","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105109_bib24","doi-asserted-by":"crossref","DOI":"10.1227\/01.NEU.0000163250.71951.18","article-title":"Risk of hemorrhage in hemangioblastomas of the central nervous system","volume":"57","author":"Gl\u00e4sker","year":"2005","journal-title":"Neurosurgery"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105109_bib25","doi-asserted-by":"crossref","first-page":"1180.e13","DOI":"10.1016\/j.wneu.2015.02.009","article-title":"Spontaneous hemorrhage from central nervous system hemangioblastomas","volume":"83","author":"Ene","year":"2015","journal-title":"World Neurosurg"},{"key":"10.1016\/j.esmoop.2025.105109_bib26","article-title":"Fatal intracranial hemorrhage with belzutifan in von Hippel-Lindau disease-associated hemangioblastoma: a case report","volume":"7","author":"Saeed","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105109_bib27","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S1470-2045(18)30487-X","article-title":"Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial","volume":"19","author":"Jonasch","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:44:02Z","timestamp":1762598642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925009780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2059702925009780"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105109","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel\u2013Lindau (VHL) disease-associated haemangioblastoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105109"}}